Pre-Conference Workshops & Engagers:
Wednesday, February 28, 2024

9:00 Morning Deep-Dive Workshop in Partnership with Foundation Medicine

Untitled design (4)

What's Next In the Future of Liquid Biopsy; featuring voices from the industry in partnership with Foundation Medicine

This workshop will cover:

  • Strategic design using ctDNA monitoring in drug development
  • Challenges in drug development with liquid biopsy
  • Bringing liquid biopsy to global markets through trials and commercialisation including IDVR experiences, HGRAC approvals, tech transfer in France, and a Japan CDx story


Session Led By:

Troy Schurr, Chief Biopharma Business Officer Foundation Medicine

Amanda Young, Senior Director, Lifecycle Product Development Foundation Medicine

Tim Burns, Vice President Translational & Data Sciences, Tyra

Jean-Francois Martini, Executive Director, Translational Oncology Lead, Global Product Development, Pfizer

Flora Berisha, Global Head, Diagnostics Partnering & Development & Precision Medicine, Johnson & Johnson Innovative Medicines

Peter Krein, Vice President, Precision Medicine, Boundless Bio


1:00pm Afternoon Deep-Dive Workshop in Partnership with GRAIL

Beyond Genotyping & Tissue: Leveraging a Liquid Biopsy, Methylation-Based Platform
Across the Cancer Care Continuum

40692 homepage banner

The need to determine whether pharma’s therapeutics will be effective in the right patients is critical to know at the earliest stages of development. GRAIL’s Methylation allows for a better representation of the activity of the tumour with an unbiased approach.

Learn how methylation can help with patient selection, monitoring and surveillance throughout the care continuum.

Opportunity to learn how methylation can be used to detect more aggressive tumours.

How to use methylation to address cancer at earlier stages than previously possible.

Using ML/AI infrastructure, knowhow and capabilities to optimise assay performance for many use cases.


Session Lead By:

Tyler Stewart, Assistant Professor, Department of Medicine UCSD

Bill Cance, Distinguished Scientist, Medical Affairs, GRAIL

Veerendra Munugalavadla, Senior Director, Translational Medicine, AstraZeneca

5:00pm Evening Thought Leadership Learn & Network Engager in Partnership with Guardant Health

Untitled design (5)

Advancing Precision Oncology on A Global Scale by Bringing Liquid Biopsy Technology to New Regions

Access to liquid biopsy and genomic profiling varies significantly across regions, mostly due to regulatory hurdles and requirements. For pharma, when launching a new therapeutic, it’s critical to understand whether or not patients can be reliably identified for targeted therapies across regions.

Now, through our partnerships with Adicon, Royal Marsden, and Vall D’Hebron, Guardant is bringing our best-in-class CGP testing to global regions.

Through this Engager, Pharma can understand Guardant’s global capabilities which would inform their global launch strategies and/or regulatory submission strategies.

This evening thought leadership engager is a unique opportunity to learn through presentations, fire-side chats and an interactive Q&A session.

Session Lead By:

Naureen Starling The Royal Marsden

Melissa Gebhardt Senior Director, Business Development Guardant Health

Vafa Amirkia Director Business Development Guardant Health

Larry Wang CFO, SVP, Head of Business Development, Adicon